Phospholipids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The phospholipids market size was valued at USD 2.09 billion in 2025 and estimated to grow from USD 2.24 billion in 2026 to reach USD 3.18 billion by 2031, at a CAGR of 7.26% during the forecast period (2026-2031). This report is Segmented by Type (Phosphatidylserine, Phosphatidylcholine, and Others), Source (Soy, Sunflower, Egg, and Others); Application (Food and Beverages, Dietary Supplements, Pharmaceutical, and Others); and Geography (North America, Europe, Asia-Pacific, South America, and the Middle East and Africa). The Report Offers Market Size and Forecasts in Value (USD Million).

Global Phospholipids Market Trends and Insights

Growing Demand in Nutraceuticals for Cognitive Health Support

The growing recognition of cognitive health importance and changing consumer lifestyles are driving demand for brain health nutraceuticals. Phospholipids have become essential ingredients due to their role in neural function and structure. The European Food Safety Authority recommends a daily choline intake of 400 mg, which is higher than typical dietary consumption, indicating a significant market opportunity for phospholipid supplements. Companies are developing specialized formulations to address various cognitive health requirements. In 2024, Indena introduced Virtiva Plus, which combines Ginkgo biloba extract with phosphatidylserine, illustrating the market's shift toward premium, specialized products. The phospholipids market is expanding into stress management and sports nutrition segments, as younger consumers seek cognitive performance enhancement through phospholipid supplements. This trend strengthens phospholipids' position as high-value, multifunctional ingredients in the global nutraceutical market.

Surging Vegan and Plant-Based Phospholipid Sources

The increasing preference for plant-based phospholipid sources is driven by sustainability concerns and allergen avoidance requirements, which are changing supply chain patterns. The non-GMO foods market is projected to experience significant growth in the forecast period through the end of this decade, supporting the demand for sunflower-derived phospholipids. The adoption of ethanol-based extraction methods instead of hexane extraction aligns with current EU regulations on food processing solvents. This transition in extraction methodology demonstrates the industry's adaptation to regulatory requirements while maintaining production efficiency and product quality. The market continues to evolve as manufacturers invest in sustainable practices and alternative processing methods to meet consumer demands and regulatory standards.

High Cost of Pharmaceutical Grade Phospholipids

High prices of pharmaceutical-grade phospholipids significantly constrain market growth, particularly in emerging economies where cost concerns restrict their widespread adoption across various therapeutic applications. Croda's Life Sciences segment reported sales of EUR 504.3 million in 2024, representing a 16% decline, with phospholipids contributing only 1% of total sales, demonstrating the substantial challenges in maintaining profitability for high-specification products. The stringent quality-by-design requirements for pharmaceutical lipid formulations impose substantial regulatory compliance costs, which smaller manufacturers find increasingly difficult to manage, ultimately driving consolidation trends among suppliers in the market.

Other drivers and restraints analyzed in the detailed report include:

• High Demand in Infant Nutrition Products
• Rising Demand of Phospholipids in Drug Delivery Systems
• Complex Extraction and Refining Process

Segment Analysis

Phosphotidylcholine holds 42.98% of the market share in 2025, primarily due to its use in cognitive health supplements and pharmaceutical formulations. Its function as a choline source for acetylcholine synthesis, which supports memory and learning, has been validated through extensive research. The segment's market position is strengthened by regulatory approvals across multiple regions, making it difficult for alternative phospholipid types to gain significant market share.

Phosphotidylserine is projected to grow at 7.78% CAGR through 2031, driven by increased adoption in sports nutrition products and new research demonstrating its stress management benefits. The compound's growing popularity in athletic performance supplements and mental wellness products has created new opportunities for manufacturers and suppliers in the phospholipid market.

Complete Report Scope:

• By Type
  • Phosphotidylserine
  • Phosphotidylcholine
  • Others
• By Source
  • Soy
  • Sunflower
  • Egg
  • Others
• By Application
  • Food and Beverage
  • Dietary Supplements
  • Pharmaceutical
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Netherlands
    • Italy
    • Sweden
    • Poland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Singapore
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Chile
    • Colombia
    • Peru
    • Rest of South America
  • Middle East and Africa
    • United Arab Emirates
    • South Africa
    • Nigeria
    • Saudi Arabia
    • Egypt
    • Morocco
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

North America holds a dominant 32.10% market share in 2025, driven by advanced pharmaceutical research and development infrastructure, supportive regulatory frameworks, and established nutraceutical markets. The region's prominence is reinforced by investments in mRNA vaccine technologies and drug delivery systems, as evidenced by Moderna's USD 3.1 billion net product sales in 2024, validating the commercial success of phospholipid-based therapeutics. The region's leadership position is further strengthened by its robust supply chain infrastructure, established research institutions, and strong collaboration between industry and academia in developing innovative phospholipid applications.

Asia-Pacific exhibits the highest growth rate at 7.66% CAGR through 2031. This growth stems from expanding middle-class populations, rising health awareness, and improved regulatory frameworks that support market entry for new phospholipid ingredients. China's National Health Commission's 2024 approval of L-alpha-Glycerylphosphorylcholine as a food raw material demonstrates regulatory support that enhances market opportunities. The streamlined approval process in China, featuring reduced review periods and higher acceptance rates, presents significant expansion opportunities for international phospholipid suppliers. The region's rapid industrialization, increasing healthcare expenditure, and growing focus on preventive healthcare further accelerate market growth.

Europe maintains consistent growth despite complex regulations. The European Commission's revised infant formula regulations influence phospholipid applications, while regional sustainability initiatives increase demand for plant-based phospholipid sources that meet environmental standards. The region's mature market characteristics, combined with stringent quality standards and emphasis on sustainable production methods, create a stable but competitive environment for phospholipid manufacturers and suppliers.

List of Companies Covered in this Report:

• Cargill, Incorporated
• VAV Life Sciences
• Lipoid GmbH
• DSM-Firmenich
• Kemin Industries
• Matlani Group (Sonic Biochem)
• BOC Sciences
• Matrix Life Science
• Botanic Healthcare Pvt. Ltd. (LipsoBio)
• ChemFaces
• Amitex Agro Product Pvt. Ltd.
• Croda International Plc (Croda Pharma)
• Creative Biolabs
• Agro Solvent Products Pvt Ltd (Sun Nutrafoods)
• Fengchen Group Co.,Ltd
• Biosynth
• Merck KGaA
• Chemi S.p.A.
• FUJIFILM Corporation (FUJIFILM Wako Pure Chemical Corporation)
• Nippon Fine Chemical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support